Phase II trial with chlorozotocin in advanced colorectal cancer

Bleiberg, Harry; Rozencweig, Marcel; Michel, Jeffrey; Clavel, M.; Longeval, E.; Feremans, Walter; Bondue, H.; Lardinois, J.; Crespeigne, N.; Kenis, Yvon

doi:10.1016/0014-2964(81)90306-6

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of leukopenia and thrombocytopenia at each dose level in patients with varying levels of performance status failed to show the relationship of toxicity to performance status noted by Bleiberg (2). Significant vomiting was reported by 30% of patients receiving 200 or 225 mg/m 2.…”

Section: Resultsmentioning

confidence: 98%

“…Chlorozotocin (CZT) has been tested against colorectal adenocarcinomas at doses of 120 to 150 mg/m 2 in 39 patients with no prior chemotherapy producing two partial responses (1); at 200 mg/m 2 in 23 previously-treated patients with 2 partial responses (2); and at 120 mg/m 2 in 14 previouslytreated patients with 2 partial responses (3). The Southwest Oncology Group has further evaluated CZT at maximum tolerable doses (4) in patients with little and no prior chemotherapy and at low doses in patients with extensive prior chemotherapy.…”

Section: Introduction Patients and Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Chlorozotocin: results in colorectal carcinoma treated with high and low doses

et al. 1984

View full text Add to dashboard Cite

Clorozotocin was evaluated in patients with advanced colorectal cancer at 225 mg/m2 every six weeks in 14 patients with no prior treatment, at 200 mg/m2 in 43 patients with normal tolerance of prior chemotherapy, and at 100 mg/m2 in 38 patients with extensive or poorly tolerated prior therapy. Median survival for the respective groups was 192, 107 and 79 days; these differences are best explained as a function of performance status. Partial response was reported for one patient, 15 had disease stabilization and two had improvement short of partial remission. Myelotoxicity was acceptable at all doses, with thrombocytopenia being dose limiting at 225 mg/m2. Four patients developed azotemia during or after chlorozotocin treatment. Chlorozotocin has minimal activity against colorectal carcinomas and no dose-response relationship is evident.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Introduction Patients and Methodsmentioning

confidence: 99%

Chlorozotocin: results in colorectal carcinoma treated with high and low doses

et al. 1984

View full text Add to dashboard Cite

show abstract

“…Occasional responses in man have been noted in malignant melanoma (41, lymphoma [4-71, renal carcinoma [6,8], colon carcinoma 191, and breast carcinoma [9] with either 1-day [4,5,7] or 5-day [6] administration schedule. Two disease-oriented phase I T studies of CLZ given in a single dose every 6 weeks in colon carcinoma have failed to show activity against this tumor type [10,11]. The efficacy and the toxicity of CLZ administered for 5 consecutive days to patients with advanced, unresectable GI cancer are the subject of this report.…”

Section: Introductionmentioning

confidence: 99%

Chlorozotocin treatment of advanced gastrointestinal cancer

Veronesi¹,

Magri²,

Tirelli³

et al. 1983

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

From April 1981 to December 1981, 34 consecutive patients with advanced gastrointestinal cancer were treated with chlorozotocin at the dosage of 40 mg/m2 daily for 5 consecutive days (30 mg/m2 in patients pretreated with chemotherapy) every 6 weeks. In the 30 patients evaluable for response, a 3.3% objective response rate was encountered. Toxicity was not significant and consisted mainly in reversible myelosuppression. Median survival was 3 months. At the dosage and schedule used, chlorozotocin does not seem to be an effective agent in the treatment of advanced gastrointestinal cancer.

show abstract

Reporting Results From Chemotherapy Trials

Oye¹

1984

JAMA

View full text Add to dashboard Cite

Phase II trial with chlorozotocin in advanced colorectal cancer

Cited by 4 publications

References 5 publications

Chlorozotocin: results in colorectal carcinoma treated with high and low doses

Chlorozotocin: results in colorectal carcinoma treated with high and low doses

Chlorozotocin treatment of advanced gastrointestinal cancer

Reporting Results From Chemotherapy Trials

Contact Info

Product

Resources

About